124 related articles for article (PubMed ID: 38497396)
21. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors.
Rosenblum RE; Harris CK; Baeg KJ; Starr JA; Brais LK; Stashek KM; Ward SC; Katona BW; Clancy TE; Wisnivesky JP; Kulke MH; Metz DC; Kim MK; Chan JA
Pancreas; 2020 Feb; 49(2):249-254. PubMed ID: 32011530
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
23. Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice.
van Beek DJ; Pieterman CRC; Wessels FJ; van de Ven AC; de Herder WW; Dekkers OM; Zandee WT; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
Front Endocrinol (Lausanne); 2022; 13():926491. PubMed ID: 36277719
[TBL] [Abstract][Full Text] [Related]
24. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
[TBL] [Abstract][Full Text] [Related]
25. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
[TBL] [Abstract][Full Text] [Related]
27. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
[TBL] [Abstract][Full Text] [Related]
28. EUS-guided FNA cytology of pancreatic neuroendocrine tumour (PanNET): a retrospective study of 132 cases over an 18-year period in a single institution.
Chen S; Lin J; Wang X; Wu HH; Cramer H
Cytopathology; 2014 Dec; 25(6):396-403. PubMed ID: 24635775
[TBL] [Abstract][Full Text] [Related]
29. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
[TBL] [Abstract][Full Text] [Related]
30. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
Lopez-Aguiar AG; Zaidi MY; Beal EW; Dillhoff M; Cannon JGD; Poultsides GA; Kanji ZS; Rocha FG; Marincola Smith P; Idrees K; Beems M; Cho CS; Fisher AV; Weber SM; Krasnick BA; Fields RC; Cardona K; Maithel SK
Ann Surg Oncol; 2019 Aug; 26(8):2517-2524. PubMed ID: 31004295
[TBL] [Abstract][Full Text] [Related]
31. Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors.
Paiella S; Impellizzeri H; Zanolin E; Marchegiani G; Miotto M; Malpaga A; De Robertis R; D'Onofrio M; Rusev B; Capelli P; Cingarlini S; Butturini G; Davì MV; Amodio A; Bassi C; Scarpa A; Salvia R; Landoni L
World J Gastroenterol; 2017 May; 23(17):3092-3098. PubMed ID: 28533666
[TBL] [Abstract][Full Text] [Related]
32. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
[TBL] [Abstract][Full Text] [Related]
33. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.
Krauss T; Ferrara AM; Links TP; Wellner U; Bancos I; Kvachenyuk A; Villar Gómez de Las Heras K; Yukina MY; Petrov R; Bullivant G; von Duecker L; Jadhav S; Ploeckinger U; Welin S; Schalin-Jäntti C; Gimm O; Pfeifer M; Ngeow J; Hasse-Lazar K; Sansó G; Qi X; Ugurlu MU; Diaz RE; Wohllk N; Peczkowska M; Aberle J; Lourenço DM; Pereira MAA; Fragoso MCBV; Hoff AO; Almeida MQ; Violante AHD; Quidute ARP; Zhang Z; Recasens M; Díaz LR; Kunavisarut T; Wannachalee T; Sirinvaravong S; Jonasch E; Grozinsky-Glasberg S; Fraenkel M; Beltsevich D; Egorov VI; Bausch D; Schott M; Tiling N; Pennelli G; Zschiedrich S; Därr R; Ruf J; Denecke T; Link KH; Zovato S; von Dobschuetz E; Yaremchuk S; Amthauer H; Makay Ö; Patocs A; Walz MK; Huber TB; Seufert J; Hellman P; Kim RH; Kuchinskaya E; Schiavi F; Malinoc A; Reisch N; Jarzab B; Barontini M; Januszewicz A; Shah N; Young WF; Opocher G; Eng C; Neumann HPH; Bausch B
Endocr Relat Cancer; 2018 Sep; 25(9):783-793. PubMed ID: 29748190
[TBL] [Abstract][Full Text] [Related]
34. Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis.
Du B; Wang X; Zhang W; Tan Q; Wei Y; Shao Z
ANZ J Surg; 2022 Apr; 92(4):787-793. PubMed ID: 34723424
[TBL] [Abstract][Full Text] [Related]
35. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
37. CD47 expression and CD163
Imam R; Chang Q; Black M; Yu C; Cao W
BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
[TBL] [Abstract][Full Text] [Related]
38. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors.
de Mestier L; Armani M; Cros J; Hentic O; Rebours V; Cadiot G; Sauvanet A; Couvelard A; Lebtahi R; Ruszniewski P
Dig Liver Dis; 2019 Dec; 51(12):1720-1724. PubMed ID: 31350186
[TBL] [Abstract][Full Text] [Related]
39. [Accurate grading of pancreatic neuroendocrine tumors with Ki-67 index in fine-needle aspiration specimens: a comparative cytologic and histologic study].
He SR; Cui D; Gong H; Zhu YP; Chen L; Hu ST; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):393-399. PubMed ID: 28591986
[No Abstract] [Full Text] [Related]
40. Reliability of Ki-67 Determination in FNA Samples for Grading Pancreatic Neuroendocrine Tumors.
Díaz Del Arco C; Díaz Pérez JÁ; Ortega Medina L; Sastre Valera J; Fernández Aceñero MJ
Endocr Pathol; 2016 Dec; 27(4):276-283. PubMed ID: 27688080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
